Lure Of Niche Drugs Leads India's Cadila To Buy Troubled KV Pharma's Generic Arm For $60 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
With the acquisition of Nesher Pharmaceuticals, Cadila hopes to gain a strong footing in the high-barrier but lucrative controlled substance market, which is estimated at $7 billion.
You may also be interested in...
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced April 1 it has cut the list price of its new preterm birth prevention drug Makena (hydroxyprogesterone caproate) by 54% – from $1,500 to $690 per injection – effective immediately.
Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News
Pankaj Patel, chairman and managing director of India's fifth-largest firm Cadila Healthcare expresses an unswerving support for growth through partnerships. Riding on an early partnership with Swiss firm Nycomed and lucrative opportunities in niche segments like vaccines, Cadila's growth has been extraordinary - 18-fold growth in the last 15 years.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.